Proactive Investors - Run By Investors For Investors

e-therapeutics sees full-year operating loss significantly reduced as turnaround continues under new CEO

Ray Barlow, who joined as e-therapeutics CEO on 6 April 2017 commented: "During the course of the year, we have continued the turnaround of the business. We are now focused on the right activities"
Search sign
e-therapeutics saw its full-year operating loss reduced to £6.8mln, down from a £16.3mln loss a year earlier

e-therapeutics PLC (LON:ETX) saw its operating loss significantly reduced in the year ended 31 January 2018, having undertaken a  systematic review of its operations under new CEO Ray Barlow.

The AIM-listed drug discovery company saw its full-year operating loss reduced to £6.8mln, down from a £16.3mln loss a year earlier, with an R&D tax credit of £1.4mln lower than the £3.1mln in the previous year.

READ: e-Therapeutics enhances its AI technology capabilities as it signs two collaboration deals

The firm’s cash and deposits at its year-end were £9.6mln, down from £14.0mln a year earlier, but with the cash and deposits reduction of £4.4mln less than the £10.8mln reduction the year before.

Barlow, who joined as e-therapeutics CEO on 6 April 2017 commented: "During the course of the year, we have continued the turnaround of the business. We are now focused on the right activities. With prudent cost control, we are creating as many opportunities for value creation as our current resources allow.”

He added: Our business development efforts are beginning to bear fruit and we are now viewed as a serious and credible innovator with a unique set of technologies and assets.

"In the coming year, we will continue to take a pragmatic approach to explore all avenues of value creation for our Shareholders. We are increasingly optimistic about our future."

View full ETX profile View Profile

e-Therapeutics plc Timeline

CN Video
March 28 2018

Related Articles

porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
pills
November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use